I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q3, the actual value is USD 1.494 M.
EPS: As of FY2026 Q3, the actual value is USD -0.08.
EBIT: As of FY2026 Q3, the actual value is USD -8.852 M, missing the estimate of USD -7.547 M.
Revenue
Citius Oncology, Inc. reported $1.5 million in revenue for the three months ended June 30, 2026, compared to no revenue in the prior-year quarter. For the nine months ended June 30, 2026, revenue was $7.1 million, also compared to no revenue in the prior-year period.
Gross Profit
Gross profit was $1.0 million for the three months ended June 30, 2026, and $5.5 million for the nine months ended June 30, 2026.
Operating Expenses
Research and Development (R&D) expenses were $0.2 million for the three months ended June 30, 2026, a decrease from $0.9 million in the prior-year quarter. For the nine months ended June 30, 2026, R&D expenses were $2.3 million, down from $5.3 million in the prior-year period. General and Administrative (G&A) expenses increased to $4.2 million for the three months ended June 30, 2026, from $1.9 million in the prior-year quarter, reflecting commercial organization expansion. Nine-month G&A expenses were $30.7 million, including a $19.7 million one-time CMO contract cancellation charge.
Net Loss
Net loss for the three months ended June 30, 2026, was -$8.9 million, compared to -$5.4 million in the prior-year quarter. For the nine months ended June 30, 2026, the net loss was -$41.1 million, compared to -$19.8 million in the prior-year period.
Cash and Cash Equivalents
Citius Oncology, Inc. held $16.6 million in cash and cash equivalents as of June 30, 2026, an increase from $3.9 million as of September 30, 2025.
Cash Flows
Net cash used in operating activities for the nine months ended June 30, 2026, was -$13.9 million. Net cash used in investing activities for the same period was -$7.0 million due to license payments. Net cash provided by financing activities was $33.5 million, which included $9.7 million in net proceeds from warrant exercises and $10.0 million from a senior secured term loan facility.
Operational Metrics
Since its launch, LYMPHIR has been ordered by 44 institutions, with institutional vial orders growing 31% sequentially to 926 in the quarter ended June 30, 2026. July 2026 marked the largest order month to date with 383 vials ordered, representing a 25% increase over the prior quarter’s monthly average. Citius Oncology, Inc. has expanded its commercial organization to 29 people for nationwide coverage and secured near-universal payer coverage for LYMPHIR. Additionally, the company advanced two investigator-initiated Phase 1 studies of LYMPHIR in combination settings for recurrent or refractory gynecologic cancers and high-risk relapsed or refractory diffuse large B-cell lymphoma.
Outlook
Citius Oncology, Inc. expects continued institutional demand to drive new wholesaler orders and anticipates a robust remainder of the fiscal year. This outlook is based on the positive trajectory of formulary approvals, institutional adoption, and unit demand. The company aims to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end.